Welcome to our dedicated page for Quince SEC filings (Ticker: QNCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quince Therapeutics, Inc. (Nasdaq: QNCX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Quince’s financial condition, clinical development activities, and material corporate events related to its rare disease biotechnology programs.
For Quince, key filings include periodic reports such as Forms 10-Q and 10-K, which discuss research and development spending, cash resources, and risk factors associated with advancing eDSP and the Autologous Intracellular Drug Encapsulation (AIDE) platform. Current reports on Form 8-K highlight specific events, including quarterly financial results, amendments to the European Investment Bank credit facility, and updates tied to investor communications like the company’s virtual Investor Day.
Filings related to the pivotal Phase 3 NEAT trial in Ataxia-Telangiectasia (A-T) and other clinical programs can be important for understanding trial design, regulatory interactions, and the status of eDSP as a potential treatment. Disclosures may reference the Special Protocol Assessment (SPA) agreement with the FDA, Fast Track designation for the eDSP System in A-T, and the company’s intentions regarding future regulatory submissions, subject to study outcomes.
Stock Titan enhances these documents with AI-powered summaries that explain the main points of lengthy reports such as 10-K annual reports and 10-Q quarterly updates in straightforward language. Real-time updates from the SEC’s EDGAR system help ensure that new Quince Therapeutics filings, including Form 4 insider transaction reports and proxy materials, appear promptly. Users can review full-text filings while relying on AI-generated overviews to quickly identify items related to clinical milestones, financing arrangements, or changes in capital structure.
By combining original SEC documents with AI analysis, this page helps investors and researchers interpret Quince Therapeutics’ regulatory history and ongoing obligations as a Nasdaq-listed biotechnology company.
Quince Therapeutics, Inc. notified the SEC that it could not timely file its Annual Report on Form 10-K for the year ended December 31, 2025 because additional time is needed to complete accounting procedures and disclosures following recent headcount reductions and the negative Phase 3 clinical trial results. The company expects to file within the 15 calendar day extension permitted by Rule 12b-25.
Quince Therapeutics, Inc. has eliminated its loan obligations to the European Investment Bank by paying EUR 4,800,000, or approximately $5.5 million, on March 27, 2026. This payment settled outstanding EIB debt of approximately $16.4 million as of that date, and all obligations under the finance and guarantee agreements were fully satisfied and discharged.
The company describes this settlement as a material milestone that removes a significant debt overhang while it continues a corporate restructuring and an evaluation of strategic alternatives, including potential merger, reverse merger, asset sale, or other strategic transactions aimed at maximizing shareholder value.
Quince Therapeutics, Inc. has received two deficiency notices from Nasdaq regarding its continued listing on the Nasdaq Global Select Market. Nasdaq notified the company that its common stock failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days, giving Quince until September 14, 2026 to regain compliance by maintaining a closing bid of at least $1.00 for at least ten consecutive business days.
The company also received a notice that its market value of listed securities has been below the required $50,000,000 for 30 consecutive business days, with the same compliance deadline and ten-day cure standard. Quince may seek to transfer to the Nasdaq Capital Market or consider actions such as a reverse stock split, and it can appeal any delisting determination. For now, its stock continues to trade on the Nasdaq Global Select Market under the symbol QNCX.
Group One Trading LLC reports beneficial ownership of 5,942,906 shares of Quince Therapeutics common stock as of 02/28/2026. This holding is reported as 10.67% of the class and is shown with sole voting and dispositive power over those 5,942,906 shares. The filing states the reported total includes options to buy 6,344,500 shares and notes the filer acts as a market maker in Quince options.
Quince Therapeutics filed an 8-K outlining a failed lead drug program, a shift to strategic alternatives, and heightened financial risk. As of December 31, 2025, it preliminarily estimates $5.8 million in cash and cash equivalents, $11.9 million in short-term investments, and $16.4 million outstanding under its EIB Loan.
The company’s lead candidate eDSP failed to meet primary and secondary endpoints in the NEAT clinical trial, leaving no current product candidates or meaningful operations. Management has engaged LifeSci Capital to evaluate strategic options, focusing on a potential reverse merger, but notes there are no agreements in place and no assurance of success.
Quince warns that the only opportunity for shareholder return now depends on completing a reverse merger. It highlights risks including potential Nasdaq delisting due to its share price being below $1.00 since January 29, 2026, possible acceleration of the EIB Loan upon a Material Adverse Change, and a scenario where failure to execute a transaction could lead to bankruptcy proceedings in which common stockholders likely receive no value.
Quince Therapeutics, Inc. reported that five members of its Board of Directors — Rajiv Patni, Luca Benatti, Margi McLoughlin, Una Ryan, and June Bray — resigned effective January 30, 2026. The company states these resignations were not due to any disagreement over operations, policies, or practices.
Quince Therapeutics, Inc. filed a current report to note that it has released top-line clinical data from a major late-stage study. On January 29, 2026, the company issued a press release with results from its pivotal Phase 3 NEAT clinical trial of eDSP in ataxia-telangiectasia, a serious inherited disorder. The press release, attached as Exhibit 99.1, contains the detailed trial outcomes and is incorporated by reference into this report.
Quince Therapeutics CEO and CMO Dirk Thye reported a new stock option grant. On January 23, 2026, he was granted an employee stock option to buy 1,000,000 shares of Quince Therapeutics common stock at an exercise price of $3.08 per share.
The filing shows Thye directly holds 1,000,000 derivative securities after this grant. The option vests in 48 equal monthly installments, with 1/48 vesting on the grant date and the remaining portions vesting on the first day of each subsequent month, so the award is scheduled to be fully vested by December 1, 2029.
Quince Therapeutics, Inc. reported that its President, Charles S. Ryan, received an employee stock option grant on January 23, 2026. The option gives him the right to buy 200,000 shares of common stock at an exercise price of $3.08 per share, with no cash paid for the grant itself.
The option vests in equal monthly installments over four years. According to the terms, 1/48th of the total shares vested on the grant date, and the remaining portions vest on the first day of each subsequent month so that all 200,000 shares are fully vested by December 1, 2029. After this grant, he directly beneficially owns 200,000 derivative securities in the form of these options.
Quince Therapeutics reported an insider equity award for executive Brendan Hannah, who serves as CBO, COO and CCO. On January 23, 2026, he received an employee stock option to buy 365,000 common shares at an exercise price of $3.08 per share, with the option expiring on January 23, 2036. The filing shows he holds 365,000 derivative securities after this grant, all owned directly.
The option vests in 48 equal monthly installments, with 1/48 of the shares vesting on the grant date and the remaining portions vesting on the first day of each subsequent month until full vesting on December 1, 2029. This reflects routine equity-based compensation for a senior officer rather than an open-market share purchase or sale.